Clinical trial
Glivec in Ph Positive Lymphoblastic Leukemia
NCT00388895 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00388895 |
|---|---|
| Title | Glivec in Ph Positive Lymphoblastic Leukemia |
| Official title | Positive Ph Acute Lymphoblastic Leucemia With Intensive Induction Chemotherapy and Glivec, Before and After the Hematopoetic Progenitor Transplant |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia, Cromosome Philadelphia Positive |
| Intervention type | Drug |
| Interventions | chemotherapy, Glivec |
| Enrollment | 35 |
| Start date | Jun 1, 2002 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Oct 17, 2006 |
| Last update posted | Nov 19, 2008 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: